Background: There is an urgent need to substitute the highly toxic compounds still in use for treatment of the encephalitic stage of human African trypanosomiasis (HAT). We here assessed the treatment with the doublet cordycepin and the deaminase inhibitor deoxycoformycin for this stage of infection with Trypanosoma brucei (T.b.).
Introduction
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a neglected tropical infectious disease that has reemerged in sub-Saharan Africa in the late 1900 ties [1, 2] . The disease is caused by subspecies of the protozoan parasite Trypanosoma brucei and is transmitted by the blood-sucking tsetse fly. Following a hemolymphatic stage with waves of parasitemia, the nervous system is involved manifested as a leukencephalitis, invariably lethal if left untreated. Drugs, which are effective at an early stage of the disease, but poorly penetrate the blood-brain barrier, are ineffective for the second stage. For treatment of the second encephalitic stage of HAT, arsenic compounds such as melarsoprol, which are associated with severe and even lethal side-effects, are still widely used. Moreover, there has been an alarming increase in melarsoprolrefractory sleeping sickness cases [3] . Dl-a-difluoromethylornithine (DFMO) is used for treating the West African form of HAT, caused by T.b. gambiense. However, this drug is given by intravenous injections, is expensive, and is not effective against T.b. rhodesiense that causes the East African form of HAT. Since the development of new drugs for HAT is not likely to occur in the immediate future, the strategy of testing drugs approved or in clinical use for other diseases should be pursued in order to identify less toxic or alternative drugs to cure second stage HAT [4] .
In contrast to most mammalian cells, trypanosomes cannot synthesize purines de novo. Instead they depend on the salvage pathway of nucleosides from the body fluids of the host [5] . The inability of trypanosomes to engage in de novo purine synthesis has been exploited as a therapeutic target. The trypanocidal potential of cordycepin (39-deoxyadenosine), a metabolite from the fungi Cordyceps spp., was noted in experiments performed in the 1970's [6, 7] . However, administration of cordycepin did not result in a complete cure from infection [8] , since cordycepin is rapidly converted to inactive 39-deoxyinosine by adenosine deaminase (ADA) in vivo [9] . Deoxycoformycin is an ADA inhibitor that can prevent degradation of cordycepin, and have come into use in combination with cordycepin for the treatment of certain malignant tumors in humans, e.g. leukemia and melanoma [10] .
Cordycepin is probably taken up by trypanosomes through transporters. Nucleoside transport systems, P1 and P2, are able to concentrate cordycepin inside the cells and has turned out to play an important role in the uptake of trypanocides [11] . Adenosine is salvaged through a two-step process in T. brucei where its intracellular cleavage to adenine is followed by phosphoribosylation to AMP, or by a high affinity adenosine kinase [12, 13] . Cordycepin is also a potent inhibitor of the mammalian poly-A polymerase, and has been shown to hamper the activity of nucleoside-stimulated protein kinase activity in Trypanosoma sp. [14] .
We have previously shown that intraperitoneal (i.p.) injection of cordycepin, together with coformycin or deoxycoformycin, can cure T.b. brucei infections in mice [15] . Treatment was effective, as recorded by the absence of parasitemia up to three weeks after the end of the treatment, even when instituted after the trypanosomes had penetrated into the brain parenchyma. The aim of the present work was to further improve treatment strategies with nucleosides, and gain knowledge on the effect of these compounds on the parasite. We could show that cordycepin is the best candidate drug selected after screening a library of 2200 nucleoside analogues for parasite differential toxicity. The minimal inhibitory concentrations of cordycepin and deoxycoformycin and the minimal number of doses required for effective treatment were then determined in mice infected with T.b. brucei. Cordycepin and deoxycoformycin treatment did also cure second stage infection with human pathogenic T.b. gambiense and T.b. rhodesiense, and oral administration of the duplet when combined with a proton pump inhibitor was effective. Cultivation of T.b. brucei with low doses of cordycepin allowed resistance to cordycepin to develop, but resistant parasites lost virulence, and no cross-resistance between cordycepin and melasoprol. suramin and pentamidine was noted. Importantly treated mice showed diminished levels of proinflammatory cytokines in the brain.
Altogether, our findings encourage the possible use of cordycepin and deoxycoformycin as an alternative for treatment of second stage HAT or melasoprol-resistant HAT.
Methods

Reagents
Cordycepin, suramin, pentamidine, omeprazole and EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) were all purchased from Sigma (St Louis, MO). Deoxycoformycin (pentostatin) was a kind gift of R. McCaffrey (Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts). Melarsoprol (Arsobal) was a gift from P. Simarro (WHO/NTD, Geneve, Switzerland). Unless otherwise indicated, all reagents were diluted in PBS, fractioned and stored at 220uC until further use.
The library of nucleoside analogs used consisted of compounds design to be inhibitors of various viral and microbial enzymes and is property of Medivir AB.
Mice
BALB/c, C57Bl/6 and RAG1 2/2 [16] (backcrossed on a C57Bl/6 background) male mice, 8-10 weeks old at the beginning of the experiments, were used. Mice were kept with food and water ad libitum under specific pathogen-free conditions. All experiments were conducted following protocols that received institutional approval and authorization by the Stockholm Region's animal protection committee.
Parasites
T.b. brucei (AnTat1.1E), T.b. rhodesiense (STIB 851) and T.b. gambiense (MBA) were kindly provided by P. Büscher (Institute of Tropical Medicine, Antwerp, Belgium). Tbat1 null parasites constructed by sequential homologous recombination of T.b. brucei Lister 427 [17] , were kindly provided by P. Maser (University of Bern, Switzerland). Lister 427 parasites were used as controls. Parasitemia was measured every 2 or 3 day in tail vein blood. Body weight and morbidity were regularly recorded.
Parasite culture and viability
Bloodstream forms of T.b. brucei, T.b. gambiense and T.b. rhodesiense freshly isolated from infected C57BL/6 mice (3 days post infection with 1610 7 parasites/mouse) were separated by DEAE-cellulose chromatography under sterile conditions [18] . T. brucei parasites were incubated in D-MEM containing 10% heatinactivated calf serum, 28 mM HEPES, 0.14% glucose, 1.5% NaHCO 3 , 2 mM L-glutamate, 0.14 mg/ml gentamycin, 0.3 mM dithiothreitol, 1.4 mM sodium pyruvate, 0.7 mM L-cysteine, 28 mM adenosine, 14 mM guanosine at 37uC.
To measure drug sensitivity, 2.5610 4 parasites were cultured in 96 flat-bottomed well culture plates with serial drug dilutions for 72 h at 37uC. Cultures (100 ml) were incubated for 2 h with 10 ml of WST-1 reagent (Roche, Mannheim, Germany). Viability was measured by the conversion of WST-1 reagent to formazan, recorded by multiwell scanning spectrophotometer at an excitation wavelength of 450 nm. A direct correlation between WST-1 reagent oxidation and parasite numbers was confirmed (data not shown).
Immunohistochemistry
Mice were deeply anesthetized with isoflurane, sacrificed and brains were dissected and snap frozen. To examine presence of trypanosomes within and outside the blood vessels in the brain,
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Biophotonic measurement of parasite dissemination
Stable recombinant Renilla luciferase expressing parasites were generated as recently described (F Claes, submitted). The use of such luciferase tagged T. brucei for real time studies of parasite dynamics was validated in vitro and ex vivo (F. Claes, PLoS NTD in press). BABLB/c mice were infected i.p. with 2610 3 luciferase tagged T.b. brucei AnTat1.1. At different days after infection, mice were anesthetized with 2.3% isoflurane, injected intraperitoneally with 100 mL of coelenterazine (2 mg/ml dissolved in methanol) (Synchem) diluted with 90 mL PBS pH 7, and light emission in photons/second/ cm 2 /steradian (p/sec/cm 2 /sr) was recorded in an IVIS Imaging System 100 (Xenogen LifeSciences) and Living Image 2.20.1 software (Xenogen) for 180 seconds. Measurements started 3-5 minutes after substrate injection to allow the spread of the coelenterazine.
Markers for apoptosis
DNA content. Briefly, following a 30 min permeabilization of trypanosomes in 10 mM phosphate buffer containing 6 mM digitonin, nuclei were stained with a 10 mg/ml propidium iodide solution in 10 mM phosphate buffer and kept on ice until measurement by flow cytometry.
DNA fragmentation. DNA fragmentation was assessed by using the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling method (Roche) as described [20] . Analysis was performed on a Becton Dickinson FACScan, and data were acquired on a minimum of 10,000 cells per sample.
Phosphatidylserine exposure. Exposed phosphatidylserine was detected on the outer membrane of cells using Annexin-VFluor (Roche) following instructions by the manufacturer. Fluorescence was measured using FACS analysis as described before [21] .
Necrosis. In order to analyze disruption of the plasma membrane after cordycepin treatment, nuclei were stained with propidium iodide (5 mg/ml) in the absence of a cell permeant and analyzed by flow cytometry.
Real time RT-PCR
Gene transcripts of several pro-inflammatory cytokines were quantified in brains from cordycepin-treated and PBS-treated, uninfected and infected mice by real time PCR. Total RNA was extracted from half of the fresh frozen brains, reverse-transcribed, and the transcripts levels quantified on an ABI Prism 7000 sequence detection system (Applied Biosystems) as described previously [16] . Ten-fold dilutions of a cDNA sample were amplified to control amplification efficiency for each primer pair. Thereafter, the threshold cycle value, Ct (the fractional cycle number at which the fluorescence reaches a fixed threshold) was obtained for all cDNA samples. The amount of transcripts of individual animal samples (n = 4 per group) was normalized to HPRT (DC t ). The relative amount of target gene transcripts was calculated using the 2 2DDCt method as described [22] . These values were then used to calculate the mean and standard error of the relative expression of the target gene mRNA in the brain of uninfected and infected mice.
Parasite DNA amplification
Total DNA was extracted from brains from treated and untreated mice using a Dneasy tissue kit (Qiagen, Duesseldorf, Germany). The amount of parasite DNA was quantified by real time PCR as described above using senso latu T. brucei primers [23] . The concentration of DNA in each sample was measured in a spectrophotometer. A correlation between parasite numbers and quantification of parasite DNA by real time PCR was determined.
Candidate genes cloning and sequencing
Total DNA from parental and resistant strains was extracted using the DNeasy tissue kit (Qiagen). Candidate genes suspected to be involved in the resistance to cordycepin were PCR amplified from total DNA using forward and reverse specific primers designed over the following annotated genes by the T. brucei genome project (Table S1 ): Adenosine kinase, Adenine phosphoribosyltransferase (APRT), Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), Poly(A) polymerase, Hexose Transporter 1 (HT1), Aminopurine Transporter (AT1 or P2), P1 family of nucleoside transporters (NT2, NT4, NT6 and NT12). PCR products were A-tailed and ligated into pGEM T-vector (Promega, Madison, WI). A set of 6 to 12 positive colonies for each gene was sequenced using the DYEnamic ET dye terminator kit and a Megabase sequencer (GE) with m13 forward and reverse primers, and when needed gene specific internal primers. Sequences were assembled and analyzed using phred-phrad and consed. Sequence analysis and comparisons between parental and resistant strains and genome-annotated versions were performed with ClustalW (www.ebi.ac.uk) and Blast2seq (www.ncbi.nlm.nih.gov). Single nucleotide polymorphisms between clones were taken into account.
Results
Screening of a nucleoside compound library
We have previously suggested that cordycepin could be used for treatment of second stage African trypanosomiasis. Whether other nucleoside analogues could have a more selective toxic effect on T.b. brucei was first studied. For this purpose we screened a library of 2200 drug-like nucleosides compounds for toxicity against T.b. brucei AnTat1.1. The screening revealed 14 hits showing toxicity for T.b. brucei at less than 1 mM concentration. Ten of these compounds were found to also be toxic for mammalian cells at these concentrations. One of the remaining compounds was identified as cordycepin. A second one was tubercidin, a nucleoside previously shown to inhibit the respiratory chain in T.b. brucei, but that induced adaptation of parasites to a glucoseindependent metabolism [24] . The two other compounds were diamines, N9trityl-1,2-diaminoethane hydrobromide and N-trityl-1,3-siaminopropane acetate, included in the library as intermediates used in the chemical synthesis of nucleoside analogues.
Subsequently, the trypanocidal activity of cordycepin was compared with that of adenosine deaminase resistant nucleoside analogues. Such nucleosides could potentially act as stand-alone drugs in treatment of T.b. brucei infections. Three out of 22 tested compounds showed at least 3 log higher toxicity for T.b. brucei as compared to mammalian HL-cells ( Figure 1A -B and data not shown). One is 2-fluorodeoxyadenosine and the other are two synthetic cordycepin derivatives: 6-N-(phenylthio)-methyl-cordycepin (cordycepin 110) and 6-N-(4-N-acethylbenzylthio)-methylcordycepin (cordycepin 116). As expected, deoxycoformycin was not toxic for T.b. brucei (data not shown).
The two synthetic derivatives of cordycepin were tested in vivo. Cordycepin 116, but not cordycepin 110, showed anti-trypanosomal effect during the early stage of infection ( Figure 1C ). However, no curative effect was observed when 2 mg/kg/d cordycepin 116 was inoculated during 10 days in the absence of deoxycoformycin Figure 1D ). Thus, we decided to restrict our further evaluation of the effects of treatment to cordycepin during infection with T. brucei on the host and the parasite.
Determination of minimal effective cordycepin concentrations
Experiments were then performed to confirm, using more extended protocols, the curative effect of cordycepin and deoxycoformycin on the second stage murine infection with T.b. brucei. In order to detect the presence of remnant parasites in the tissues of treated animals, immunodeficient RAG-1 2/2 mice were inoculated i.p. with blood or brain tissue homogenates of infected and treated mice. A double immuno-labelling method using antibodies against trypanosomes and cerebral endothelial cells was used to detect parasites in the brain parenchyma. Stained sections from brain of treated animals (4 per animal) were analyzed. Parasite DNA in whole blood or brain tissues was measured by real time PCR.
In a first experiment we showed that none of the C57Bl/6 mice (n = 9) treated i.p. with 2 mg/kg body weigth (kg)/day (d) cordycepin and 0.2 mg/kg/d deoxycoformycin for 7 consecutive days, starting at day 20 after infection with 2610 3 T.b. brucei. displayed parasites at 85 days of infection (65 days after treatment).
No parasites were detected in the blood of cordycepin-and deoxycoformycin-treated mice. On the contrary, although no parasites were detected directly after treatment with 20 mg/kg suramin, the presence of parasites was recorded at least once in the blood of all suramin-treated mice before sacrifice (65 days after treatment), although only in a fraction of mice at a given time.
Whereas all RAG1 2/2 mice inoculated with blood or brain homogenates from suramin-treated mice showed parasites early after infection, no parasites were detected in mice inoculated with either blood or brain homogenates from cordycepin-and deoxycoformycin-treated mice. Parasite DNA could not be amplified and parasite antigens were not detected in the brain tissues of cordycepin-and deoxycoformycin-treated mice. Infected and non-treated mice showed signs of morbidity before day 32 after infection. No mortality was recorded in the cordycepin-treated group and 1 out of 8 suramin-treated mice died 79 days after infection.
In a second experiment the minimal effective concentration of cordycepin was determined. For this purpose, we compared the treatment of mice given different doses of cordycepin and a constant dose of deoxycoformycin. Mice were inoculated with 2, 1.2 and 0.6 mg/kg/d cordycepin plus 0.2 mg/kg/d deoxycoformycin for 7 days starting at day 20 after infection. Whereas the trypanocidal effect was evident in all groups of mice (n = 9), a dosedependent effect was observed, with doses lower than 2 mg/kg/d (Figure 2A) . One out of 9 mice inoculated with 2 mg/kg/d cordycepin showed parasites before 80 days after infection.
Next, groups of mice (n = 7) were dosed with 2 mg/kg/d cordycepin and 0.2 mg/kg/d deoxycoformycin during 3, 5 or 7 days starting 20 days after infection. Again, a dose-dependent trypanocidal effect was observed also in this experiment. Five or three doses were not enough to completely clear infection, whereas in the group treated with 7 doses only one animal remained infected ( Figure 2B ). Since, a total of 2 of out of 25 mice in the different experiments treated with 2 mg/kg/d cordycepin and 0.2 mg/kg/d deoxycoformycin for 7 days remained infected after treatment, we concluded that this treatment is on the brink of the minimal effective dose for clearance. We then increased the number of doses used for treatment. When mice (8 per group) were treated for 10 or 15 days with 2 mg/kg/d cordycepin and 0.2 mg/kg/d deoxycoformycin starting at day 20 after infection, a complete curative effect was achieved in two independent experiments (33 mice together) ( Figure 2B and data not shown) .
The brucei was thus tested. We found that oral administration of 5 or 15 mg/kg/d cordycepin with 0.2 mg/kg/d deoxycoformycin cured approximately 50% of the treated mice when treatment was started at the day of infection and continued for 3 days. While oral administration of cordycepin has been shown to be an effective anti-tumoral agent [25] , deoxycoformycin has a well described acid-lability that has hampered its use in oral formulations. Cordycepin and deoxycoformycin were then administered with omeprazole, a proton pump inhibitor, to reduce acid concentration in the stomach and thereby allow absorption of enhanced concentrations of the ADA inhibitor. Daily treatment of mice at the day of infection with cordycepin plus deoxycoformycin in presence of omeprazole for 5 days resulted in cure of the infection of all (n = 6) treated mice ( Figure 4A 
Cordycepin and deoxycoformycin treatment of infections with human pathogenic T. brucei isolates
We then studied whether late stage infection with human pathogenic strains of T. brucei can be treated with cordycepin and deoxycofomycin. Two weeks after infection with 10 4 T.b. rhodesiense STIB 851 isolate, parasites were detected in the brain parenchyma. Parasite density in the brain parenchyma increased at later times of infection ( Figure 5A, B) . Parasitemia levels were low or undetectable compared to T.b. brucei AnTat1.1 ( Figure 5 C) , but mice lost weight and showed signs of morbidity at 35-40 days after infection (data not shown). Ten days of dosing of 2 mg/kg/d Thus, treatment with cordycepin and deoxycoformycin was effective in treatment of late stage infection with both human pathogenic subspecies.
Cordycepin and deoxycoformycin treatment diminished accumulation of pro-inflammatory cytokines in the brain
Brains from T.b. rhodesiense-infected mice treated with cordycepin and deoxycoformycin starting 20 days after infection contained diminished levels of IFN-c, IL-1b, IL-6 and TNF-a mRNA compared to untreated infected controls when measured 10 days after treatment ( Figure 6A-D) . Likewise, brains from mice infected with T.b. rhodesiense and treated with cordycepin and deoxycoformycin starting 20 days after infection with T.b rhodesiense contained lower levels of pro-inflammatory cytokine transcripts when studied after 80 days after infection, as compared to nontreated infected groups. Cytokine mRNA levels in infected and cordycepin and deoxycoformycin-treated mice and in uninfected mice were similar. (Figure 6E-H) .
Cordycepin-induced programmed cell death of parasites
The mechanisms accounting for the trypanocidal effect of cordycepin were subsequently explored. Several trypanocidal drugs have been shown to activate a programmed cell death of T. brucei [26] . We found that incubation with 1 mM cordycepin induced degradation of DNA by measured by propidium iodide (PI) staining of permeabilized parasites. DNA degradation was detected 1 h after cordycepin treatment and it increased with time ( Figure 7A ). DNA fragments were also detected by the TUNEL assay in cordycepintreated parasites ( Figure 7C) . One of the earliest indications of apoptosis is the translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane. Parasites treated with 1 mM cordycepin showed translocation of phosphatidylserine as indicated by the binding of annexin V as early as 1 h after treatment ( Figure 7B ). On the other hand, no alterations in mitochondrial redox potential of cordycepin-treated parasites were detected ( Figure S1 ; Text S1). DNA degradation occurred in the absence of cell membrane disruption, which could only be detected 7 h after cordycepin treatment ( Figure 7D ), indicating that cordycepin induced programmed cell death of T.b. brucei which was followed by a secondary necrosis.
Cordycepin-induced drug resistance
Whether T. b. brucei can develop resistance against cordycepin was then studied. For this purpose T. b. brucei AnTat1.1 and Lister 427 were incubated with low concentrations (1 LD 50 or higher doses) of cordycepin for 72 h at 37uC. Parasites surviving the highest concentrations of cordycepin, were then further cultured for 3 days with similar or higher concentrations of cordycepin.
This procedure was repeated for four months, after which a 40-60 fold increased resistance to cordycepin, compared to the parental strain was achieved ( Figure 8A, F) .
Resistance to the nucleoside analogue was retained after culture of the resistant parasites for three weeks in absence of cordycepin, suggesting that resistance was due to genetic alterations rather than to a metabolic adaptation of the parasite (Figure 8 B, G) . Cordycepin-resistant parasites were then incubated with melarsoprol, pentamidine and suramine to determine cross-resistance. No cross-resistance with these trypanocidal drugs was observed, indicating that these trypanocidal compounds have non-overlapping molecular targets ( Figure 8C-E, H-J) . Figure 7 . Cordycepin induces programmed cell death of trypanosomes. T.b. brucei were treated for the indicated times with 1 mM cordycepin and staining with annexin V, propidium iodide (PI), and Tunel (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) was evaluated by FACS analysis. A T.b. brucei were incubated for the indicated time with 1 mM cordycepin, fixed with digitonin and stained with PI. Note presence of subG1 peaks indicative of DNA fragmentation at 1 h after treatment and extensive DNA degradation at 3 h after incubation with cordycepin. B T.b. brucei were incubated with 1 mM cordycepin, incubated at 37uC and stained with Annexin V at the indicated time points. C DNA fragmentation in individual fixed T.b. brucei before and after incubation with 1 mM cordycepin was visualized by detection of biotinylated nucleotides incorporated onto the free 39-hydroxyl residues of DNA fragments. Biotinylated nucleotides were then stained with streptavidin-FITC. As a positive control, T.b. brucei were fixed, treated with DNAse I and the fragmented DNA was labeled biotinylated nucleotides. Negative controls included cordycepin untreated labeled and unlabeled parasites. D To study necrosis after treatment of T.b. brucei with 1 mM cordycepin, nuclei were stained with propidium iodide (5 mg/ml) in the absence of a cell permeant and analyzed by FACS. doi:10.1371/journal.pntd.0000495.g007
Nucleoside Treatment of African Trypanosomiasis www.plosntds.orgCordycepin-resistant strains displayed lower growth in vitro compared to their respective parental strains ( Figure 9A, B) . In vivo, mice inoculated with cordycepin-resistant parasites showed delayed and lower parasitemia levels compared to controls (Figure 9C, D) . Parasitemia in mice inoculated with cordycepin-resistant AnTat1.1 became undetectable. Loss of weight was registered in mice infected with the parental strains but this effect was reduced in mice infected with cordycepin resistant strains (data not shown).
Sequence analysis of candidate target genes
In order to determine possible cordycepin targets we amplified, cloned and sequenced 11 candidate genes involved in uptake and salvage of adenosine analogues in resistance-induced and parental parasites. The TbAT1, TbNT2, TbNT4, TbNT6, TbNT12 nucleoside transporter genes, TbHT1 hexose transporter, TbAK adenosine kinase, TbHGPRT hypoxanthine-guanine phosphoribosyltransferase from parental and resistant strains were screened for mutations that could cause an affected or deleterious protein function.
The HT1 was selected since this hexose transporter can be inhibited by tubericidin [24] . TbNT2 is predominantly expressed when compared to other genes in P1 family. The expression of TbNT3, TbNT4, TbNT5, TbNT7, is not seen in a parental T. b. brucei strtain. It has been reported that loss of primary transporter P2 leads to over expression of TbNT4 and TbNT6 [27] . TbNT2, 4, 6 and 12 were therefore selected for sequencing.
While several polymorphisms were found, no deleterious mutations were found in the genes sequenced except for TbAT1. TbAT1 is a nucleoside adenosine transporter present in the genome of T. brucei as a 1392 bp single copy gene where both alleles have been found to be almost identical. We found two mutations in the cordycepin-resistant AnTat1.1 strain TbAT1 gene that were not present in the respective parental DNA. There was a single base insertion at position 61 and a single base deletion at position 631, that could cause synthesis of a non-functional truncated gene product were found ( Figure 10B ). Five out of 12 sequenced colonies presented the one base insertion while the other seven carried the deletion, both groups with a read coverage of 156, which confirmed the mutations. We assume that these two sequences detected correspond to the two alleles of TbAT1 carrying different mutations but rendering the same nonfunctional transporter protein.
For the cordycepin-resistant monomorphic Lister 427 strain, PCR using primers designed at the 59 and 39 ends of the gene and at the 59 and 39 UTRs were unable to amplify any product ( Figure 10A ), while the same set of primers amplified the TbAT1 gene from the parental DNA. We assume that in this case the mutations on this gene probably generated the deletion of a partial or the complete gene sequence, as amplification with internal primers although producing a PCR fragment, was not of the expected size (data not shown).
Since cordycepin resistant monomorphic (Lister 427) and pleomorphic (AnTat1.1) parasites displayed mutations in the TbAT1 gene, we tested whether this transporter affected the susceptibility of parasites to cordycepin by using TbAT1 knockout parasites. We found that resistance of cordycepin by knockout parasites was only slightly affected by the mutation, suggesting that the absence of the P2 transporter is not sufficient to explain the observed increased resistance of parasites to cordycepin ( Figure 10C ).
Discussion
We here report a preclinical evaluation of the chemotherapeutic efficiency of cordycepin and deoxycoformycin for late stage infection with T. brucei. In brief, cordycepin was selected from a direct parasite viability screening of a compound library of nucleoside analogues. The minimal effective concentrations of cordycepin and deoxycoformycin for late stage treatment in vivo were determined. Of importance, the dose of deoxycoformycin used is similar or lower to that employed in leukemia patients, and cordycepin and deoxyformycin have been tested in clinical trials in humans (R McCaffrey, Harvard Medical School, Boston, personal communication) and in preclinical studies in dogs at higher concentrations to the ones here presented [28] . The compounds could be given i.p., s.c. and orally, and our data suggests that a slow release of the compounds in vivo will improve efficacy of treatment by reducing the doses, and that enteric coating might reduce the problem of acid lability of deoxycoformycin. The nucleoside analogue treatment was also effective for treatment of late stage infections with both T.b. rhodesiense and T.b. gambiense, different to some drugs in clinical use such as DFMO Cordycepin and deoxycoformycin treatment diminished the inflammatory cytokine accumulation in the brains of infected mice. In agreement, the number of CD45+ inflammatory cells in the brain parenchyma of T. brucei-infected mice was also reduced after treatment cordycepin and deoxycoformycin [15] . We found standard parameters associated to programmed cell death in T. brucei to be similar to those described in pluricellular organisms. Programmed cell death was followed by secondary necrosis. Interestingly, programmed cell death processes have previously been shown to be activated during the life cycle of trypanosomatids, regulating parasite number in certain host tissues, in the maintenance of clonality, as a mechanism of immunomodulation and of parasite differentiation [29] . Cordycepin thus stimulates a natural process of cell death, suggesting the presence of parasite cordycepin-sensitive targets regulating such processes.
The development of this new drug combination with reduced toxicity, high activity and oral availability gives rise to renewed hope of new and safer treatments of HAT. However, the utility and longevity of these new treatments will, to a large degree, be determined by the development of parasite resistance to the drug. We found that although T.b. brucei developed resistance to cordycepin upon prolonged culture with low doses of the compound, such resistant parasites showed diminished virulence and reduced growth in vivo. Moreover, resistant parasites showed no cross resistance to melarsoprol, suramin and pentamidine in clinical use for early or late stage treatment of HAT, suggesting that cordycepin targets are different to those of the other drugs. This is of importance since a strategy to delay or prevent the development of resistance is to combine drugs that act on different targets and therefore are unlikely to show cross-resistance. Additionally, synergistic effects may arise from a combination of two drugs that act differently. In such a situation, the concentrations of the combination partners can be reduced compared with those used in a mono-therapy, which leads to better safety.
Since resistance to cordycepin was slowly increased during the four months-long culture of the parasites with the drug (data not shown), it is likely that a number of mutations had accumulated during the process. After cloning and sequencing 11 candidate genes from cordycepin-induced resistant and parental strains, we found that parasites showed altered functional mutations only in the P2 transporter encoded by the TbAT1 gene. Although mutations found in the other examined genes were present, they did not show any predicted deleterious or altered effect for the respective protein function. Cordycepin uptake has been reported to be mediated by both the P1 and P2 transporters [27] . We found however that a TbAT1 (P2) null parasite showed only slight reduction in resistance to cordycepin, suggesting that other undefined mutated genes also participate in increased sensitivity to cordycepin of parental parasites.
Since cordycepin-resistant parasites show a genetic defect in TbAT1, it was surprising that no cross resistance to pentamidine, suramin and melarsoprol was not observed: the P2 transporter has been shown to be responsible for uptake of different trypanocides such as melaminyl arsenicals, pentamidine, diminazenes, cordycepin and tubercidin [30, 31, 32, 33] . Homozygously disrupted TbAT1 null T. brucei showed two-and three-fold increases resistance to melarsoprol and melarsen [17] . Most drugs for treatment of HAT were developed in the first half of the twentieth century, and some of them would not pass current high safety standards. A safe drug that is effective in the treatment of the encephalitic stage of HAT would significantly change the control and management of sleeping sickness. The data here presented strongly suggest that the combination of cordycepin and deoxycoformycin can be used in clinical tests for treatment of African trypanosomiasis. Besides the results from the preclinical experiments described in our manuscript, cordycepin fulfills a number of requirements for to be considered a candidate drug: It is available for other purposes and cheap, it can be given orally, clinical trials of the doublet have been performed and toxicity in man at the same concentrations used in animals seems not to pose a problem.
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